SG11201400668SA - Wnt compositions and therapeutic uses of such compositions - Google Patents

Wnt compositions and therapeutic uses of such compositions

Info

Publication number
SG11201400668SA
SG11201400668SA SG11201400668SA SG11201400668SA SG11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA SG 11201400668S A SG11201400668S A SG 11201400668SA
Authority
SG
Singapore
Prior art keywords
compositions
wnt
therapeutic uses
therapeutic
wnt compositions
Prior art date
Application number
SG11201400668SA
Inventor
Tom Tong Lee
Michael J Fitch
Kevin Lai
Monica Bennett
Peter Flynn
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47883976&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201400668S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of SG11201400668SA publication Critical patent/SG11201400668SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
SG11201400668SA 2011-09-16 2012-09-14 Wnt compositions and therapeutic uses of such compositions SG11201400668SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535913P 2011-09-16 2011-09-16
PCT/US2012/055336 WO2013040309A2 (en) 2011-09-16 2012-09-14 Wnt compositions and therapeutic uses of such compositions

Publications (1)

Publication Number Publication Date
SG11201400668SA true SG11201400668SA (en) 2014-04-28

Family

ID=47883976

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400668SA SG11201400668SA (en) 2011-09-16 2012-09-14 Wnt compositions and therapeutic uses of such compositions

Country Status (10)

Country Link
US (1) US9873722B2 (en)
EP (1) EP2748190A4 (en)
JP (1) JP2014527818A (en)
KR (1) KR20140062139A (en)
CN (1) CN103998462A (en)
AU (2) AU2012308476B2 (en)
BR (1) BR112014006321A2 (en)
CA (1) CA2848841A1 (en)
SG (1) SG11201400668SA (en)
WO (1) WO2013040309A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120213744A1 (en) 2009-04-27 2012-08-23 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
KR20140038358A (en) 2011-01-11 2014-03-28 페이트 세러퓨틱스, 인코포레이티드 Novel wnt compositions and therapeutic uses of such compositions
CA2848841A1 (en) 2011-09-16 2013-03-21 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
US9732130B2 (en) 2011-09-16 2017-08-15 Ottawa Hospital Research Institute WNT7A compositions and method of using the same
EP2834868B1 (en) 2012-04-02 2023-12-27 Hydrogenics Corporation Fuel cell start up method
GB2534315B (en) * 2013-10-02 2020-08-05 Univ Leland Stanford Junior WNT compositions and methods for purification
CA2980113A1 (en) * 2014-03-28 2015-10-01 Ottawa Hospital Research Institute Wnt induced motility and enhanced engraftment of cells
EP2975047A1 (en) 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use
EP3197465A4 (en) * 2014-09-22 2018-04-25 Rush University Medical Center Compositions and methods for treating a viral infection
US10550364B2 (en) 2014-12-24 2020-02-04 Osaka University Method for producing Wnt protein and method for storing Wnt protein
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
EP3324735A4 (en) * 2015-07-22 2018-12-26 Ramot at Tel-Aviv University Ltd. Article of manufacture and methods for increasing survival of red blood cells
CA3009999A1 (en) * 2016-01-28 2017-08-03 Jill Helms Wnt compositions and methods for serum-free synthesis
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN108623692B (en) * 2017-03-20 2020-11-17 徐寒梅 Fusion protein, preparation method and application thereof
WO2019028186A1 (en) * 2017-08-01 2019-02-07 Ankasa Regenerative Therapeutics, Inc. Wnt compositions and methods of process from serum-free culturing conditions
AU2018368440B2 (en) 2017-11-16 2022-03-03 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
EP3732201A4 (en) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
CN113282524B (en) * 2021-05-08 2022-08-16 重庆大学 Configuration method and device of cache fragments and storage medium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544752A (en) 1980-09-22 1985-10-01 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young Gene therapy using targeted viral vectors.
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
EP0972029A1 (en) * 1997-03-07 2000-01-19 Human Genome Sciences, Inc. Human secreted proteins
CA2285709A1 (en) 1997-04-01 1998-10-08 The General Hospital Corporation Molecular marker for muscle stem cells
GB9828419D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel compounds
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20050130181A1 (en) 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
EP1597355A2 (en) 2002-09-24 2005-11-23 Neuro Therapeutics AB Method and materials relating to neurogenesis
WO2004091647A1 (en) 2003-04-07 2004-10-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions of active wnt protein
EP1622637A2 (en) * 2003-05-15 2006-02-08 The University of Chicago Method and compositions for nerve regeneration
EP1639097B1 (en) 2003-06-25 2013-08-07 Ottawa Health Research Institute Methods and compositions for modulating stem cell growth and differentiation
JP2008511672A (en) 2004-08-30 2008-04-17 セレゲン，インコーポレーテッド Cultured three-dimensional tissue and use thereof
WO2006036175A2 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
EP2134352A4 (en) 2007-03-05 2011-05-25 Univ Leland Stanford Junior Wnt compositions and methods of use thereof
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
CA2748716A1 (en) 2008-12-31 2010-07-08 The Regents Of The University Of California Dominant negative wnt2 compositions and methods of use
US20120213744A1 (en) 2009-04-27 2012-08-23 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
CA2786745A1 (en) 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
KR20140038358A (en) 2011-01-11 2014-03-28 페이트 세러퓨틱스, 인코포레이티드 Novel wnt compositions and therapeutic uses of such compositions
SG192182A1 (en) 2011-01-28 2013-08-30 Univ Leland Stanford Junior Wnt compositions and methods of use thereof
CA2848841A1 (en) 2011-09-16 2013-03-21 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
US9732130B2 (en) 2011-09-16 2017-08-15 Ottawa Hospital Research Institute WNT7A compositions and method of using the same

Also Published As

Publication number Publication date
WO2013040309A2 (en) 2013-03-21
WO2013040309A3 (en) 2013-05-10
EP2748190A4 (en) 2015-01-21
EP2748190A2 (en) 2014-07-02
BR112014006321A2 (en) 2017-04-11
KR20140062139A (en) 2014-05-22
AU2012308476B2 (en) 2016-04-14
AU2016201547A1 (en) 2016-03-31
CN103998462A (en) 2014-08-20
JP2014527818A (en) 2014-10-23
AU2012308476A1 (en) 2013-04-18
US20150099708A1 (en) 2015-04-09
CA2848841A1 (en) 2013-03-21
US9873722B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
HK1212729A1 (en) Riboregulator compositions and mehtods of use
EP2675471A4 (en) Hsa-related compositions and methods of use
HK1213798A1 (en) Therapeutic compounds and compositions
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
EP2536756A4 (en) Hsa-related compositions and methods of use
EP2584897A4 (en) Resveratrol-containing compositions and methods of use
HK1193837A1 (en) Polyurea compositions and methods of use
EP2603202A4 (en) Compositions and methods for treatment of taupathy
EP2836224A4 (en) Compositions of microbiota and methods related thereto
SG10201602752XA (en) Melanin modification compositions and methods of use
EP2663576A4 (en) Novel wnt compositions and therapeutic uses of such compositions
EP2836218A4 (en) Prebiotic compositions and methods of use
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
EP2772483A4 (en) 4-aminocarbazole compound and use of same
EP2667889A4 (en) Wnt compositions and methods of use thereof
EP2596112A4 (en) Acetycysteine compositions and methods of use thereof
HK1212251A1 (en) Topical compositions and methods of use
EP2917314A4 (en) Composition of oligomerate
IL227924A0 (en) Compositions and methods of use for determination of he4a
EP2753337A4 (en) Compositions including beta-glucans and methods of use
EP2906041A4 (en) Compositions and methods of use of an inappetance-controlling compound
EP2755668A4 (en) Hyr1-derived compositions and methods of treatment using same
HK1209381A1 (en) Preparation of composition comprising gas microbubbles
HK1213151A1 (en) Xanthophyll compositions and methods of use